2014 Annual Report - Lung Cancer Research Foundation

BREATHING LIFE INTO RESEARCH
BREATHING LIFE INTO RESEARCH
2014 Annual Report
1
2014 ANNUAL REPORT
The mission of the Lung Cancer Research
Foundation (LCRF) is to improve and save
lives by funding groundbreaking research
for the prevention, diagnosis, treatment
and cure of lung cancer.
BACKGROUND & APPROACH
LCRF funds innovative, high-reward research across the
spectrum of basic, clinical, and translational research that
has the potential to extend survival and improve quality
of life for people with lung cancer. Our Scientific Advisory
Board, comprised of renowned multi-disciplinary scientists
and physicians, ensures that the most promising research
is funded.
2
BREATHING LIFE INTO RESEARCH
Message from the
Chairman & Vice Chairmen
DEAR FRIENDS,
Thanks to your support, 2014 was a year of growth for the Lung Cancer Research
Foundation. We raised more than $1.6 million, allowing us to grant $1.2 million to
12 academic investigators across the United States to pursue critical lung cancer
research. We brought together lung cancer survivors, patients, families, and researchers
from top cancer centers at a number of record-breaking events, including the Ninth
Annual Lung Cancer Awareness Luncheon, which drew more than 300 people.
We also laid the foundation for an even stronger and more impactful organization
by signing a term sheet with Uniting Against Lung Cancer (UALC), which has led to
the formal merging of our two organizations. LCRF was founded in 2005 by Laurie
Carson, who tirelessly advocated for increased lung cancer research after the disease
claimed the lives of both her brother and uncle. UALC was also born out of a personal
connection to lung cancer; family and friends of Joan Scarangello McNieve, a journalist
who died of the disease at the age of 47, founded the organization. Similar to LCRF,
UALC has a long history and strong track record of funding innovative lung cancer
research. Given our shared passion and mission, the two organizations agreed to
combine our expertise, resources, and network of committed supporters to make an
even greater impact. Nancy Sanford joined LCRF as Executive Director with 25 years
of fundraising experience, most recently as the Vice President and Chief Philanthropy
Officer of the Alzheimer’s Drug Discovery Foundation.
Pippa G. Gerard
With this report, it is a privilege to update you on the activities of both LCRF and
UALC during 2014. We are confident that our individual accomplishments will serve
as prologue for our next chapter—one that we will write together.
Thank you for your continued support, without which our work would not be possible.
Together, we can help close the funding gap for lung cancer research, bringing hope
to those with the disease and their loved ones.
Mary Ann Tighe
Sincerely,
PIPPA G. GERARD
Chairman, LCRF
MARY ANN TIGHE
Vice Chairman, LCRF
Former Chairman, UALC
KIMBERLY KRAVIS
Vice Chairman, LCRF
Kimberly Kravis
3
2014 ANNUAL REPORT
Investing in the Scientific Advances of Tomorrow
LCRF is proud to fund the most promising research that will lead to better prevention, screening and
treatment of lung cancer. Funded investigators are pursuing a variety of scientific study including
furthering understanding of lung cancer biology, developing more targeted therapies, and alleviating
the psychosocial impact of lung cancer.
OUR IMPACT BY THE NUMBER S
2014 GRANT OVERVIEW
20 grants
$1 million
AWARDED BY LCRF
AWARDED BY LCRF
12 grants
$1.2 million
AWARDED BY UALC
AWARDED BY UALC
LCRF INVESTIGATOR BREAKDOWN
UALC INVESTIGATOR BREAKDOWN
40%
35%
Young investigators
40%
25%
42%
33%
42%
Junior investigators
25%
112
grants
35 Experienced investigators
51
institutions
25%
Junior investigators
25%
%
LCRF CUMULATIVE IMPACT
Young investigators
33%
Experienced investigators
UALC CUMULATIVE IMPACT
$5.6
million awarded
134
grants
57
institutions
$13
million awarded
RESEARCH HIGHLIGHTS
WARREN DENNING, PHD | LCRF
University of Texas, MD Anderson Cancer Center
Dr. Denning’s project is investigating
a novel way to treat small cell lung cancer,
an aggressive growth accounting for
around 15 percent of newly diagnosed
lung cancer. Dr. Denning and his team are
working to modify T cells in a patient’s
immune system to help them better detect,
bind to, and eliminate cancer cells.
4
MONTE WINSLOW, PHD | UALC
Stanford University
Dr. Winslow is working to address the lack
of drugs that specifically kill metastases,
a major impediment to successful lung
cancer therapy. Dr. Winslow’s project, using
recent revolutionary advances in genomic
technologies, aims to uncover critical new
vulnerabilities that could be exploited
to eradicate metastases and significantly
improve lung cancer patient outcomes.
BREATHING LIFE INTO RESEARCH
Dr. Katerina Politi at work
in her lab at Yale University
FROM GRANTEE TO LCRF SCIENTIFIC ADVISORY BOARD MEMBER
From an early age, Dr. Katerina Politi was fascinated by biology
and genetics. In particular, she was captivated by the ability
of cancer cells to change, adapt, and proliferate throughout the
body. “I think that’s really what motivated me to study cancer
itself—the biology of the disease was so intriguing.”
After studying biology at the University of Pavia in Italy, Dr. Politi
obtained her PhD in Genetics and Development at Columbia
University. She then joined Nobel Prize-winning scientist Harold
Varmus’ lab at Memorial Sloan-Kettering Cancer Center. It was
there that she began her work on the molecular basis of lung
cancer—work she continues today at Yale University as an
Assistant Professor in the Department of Pathology and Medicine
and a Member of the Yale Cancer Center.
Dr. Politi received funding from UALC in 2010 and LCRF in 2013,
during which time she was establishing her own lab. “The UALC
funding I received was devoted to understanding mechanisms
of resistance to a specific drug combination,” said Dr. Politi.
“Through this research, we were able to determine that this
drug combination could potentially be used as a front-line
therapy in the treatment of lung cancer.” Her LCRF grant enabled
research into even more complex methods of resistance.
“If we understand how tumors change to become resistant,
then we will have a much better hope of learning to reverse
those changes,” said Dr. Politi. Both grants have led to followon funding from the federal government to continue this
important work.
In 2014, Dr. Politi joined UALC’s Medical Committee, which was
responsible for reviewing grant applications received by the
Foundation. After the merger of UALC and LCRF in 2015, she
became a member of LCRF’s newly integrated Scientific
Advisory Board, whose members are responsible for reviewing
applications for the merged organization. In addition, Dr. Politi
recently joined the Scientific Steering Committee, a group
tasked with providing guidance and review of the LCRF’s
Scientific Grant Program. “It’s an exciting opportunity to help
shape the organization’s grant portfolio, both through selecting
the projects that get funded and by figuring out the best
funding mechanisms to support the science,” said Dr. Politi.
“It’s also nice to be connected to the people who support
lung cancer research. It really gives a lot of meaning to the day
in and day out of laboratory scientists.”
Dr. Politi’s research into the molecular basis of lung cancer
is ongoing. Her lab at Yale University is an integral part of
a recently awarded Specialized Program of Research Excellence
(SPORE) grant from the National Cancer Institute. Current work
in Dr. Politi’s laboratory is focused on better understanding
the causes of resistance to new and existing therapies, as well
as understanding biological features of lung tumors that make
them susceptible to specific treatments.
Dr. Politi strongly believes that foundations are vital to
attracting, engaging, and retaining lung cancer scientists
such as herself. “Foundations like LCRF can play a critical
role in helping a researcher, whether it be an established
investigator or a junior scientist, get a novel idea off
the ground.”
5
2014 ANNUAL REPORT
Collective Impact: Signature Events
to Raise Awareness and Funds
STRIDES FOR LIFE 2014
August 10, 2014, Southampton, NY
The ninth annual Strides for Life welcomed more than
700 participants, raising $480,000 for lung cancer awareness
and research. Walkers and runners of all ages participated in the
3-mile event in honor of lung cancer survivors or in memory
of those who have passed.
LEFT Racers take off at the starting line.
BOTTOM LEFT Team Dinah at the finish line.
BOTTOM RIGHT Team Sonia at the finish line.
NINTH ANNUAL LUNG CANCER
AWARENESS LUNCHEON
November 4, 2014, New York, NY
LCRF’s ninth annual Lung Cancer Awareness Luncheon, held
at the Pierre Hotel in New York City, brought together 300
guests and raised more than $700,000. Charles M. Rudin, MD,
PhD, Chief of the Thoracic Oncology Service at Memorial
Sloan Kettering Cancer Center, served as keynote speaker
and recipients of 20 research grants totaling $1 million were
announced. Warren Denning, PhD, a 2014 grant awardee
from MD Anderson Cancer Center in Houston, received the
prestigious Scientific Merit Award for his project investigating
the use of the immune system in the treatment of small
cell lung cancer.
RIGHT (From left to right) Laure Sudreau-Rippe, Pippa G. Gerard,
James B. Dougherty, MD, Nancy M. Sanford, Kimberly Kravis,
and Rose Ann Weinstein.
6
“All LCRF grants represent an opportunity to turn
good ideas into good therapies, a chance to make
the ephemeral actual, and bring a part of the future
into the present—and that is powerful.”
–Warren Denning, PhD
BREATHING LIFE INTO RESEARCH
12TH ANNIVERSARY STROLLING SUPPER
WITH BLUES & NEWS
November 18, 2014, New York, NY
The 12th anniversary Strolling Supper was UALC’s most
successful gala to date, raising over $1.4 million. More than 500
guests gathered at Gotham Hall to benefit lung cancer research.
NBC’s Brian Williams, a long-time UALC supporter, returned
as the event’s host and honorary chairman. Additionally,
WABC-TV News Anchor Bill Ritter returned as the gala’s emcee.
Guests enjoyed a silent auction packed with luxury items
and once-in-a-lifetime experiences, a rousing performance
by Grammy award-winning blues artist Delbert McClinton,
and savory food and cocktails.
TOP David A. Hidalgo, MD, Mary Ann Tighe, Aaron M. Tighe.
BOTTOM LEFT Bill Ritter, WABC-TV Eyewitness News Anchor.
BOTTOM RIGHT Strolling Supper at Gotham Hall.
ELLIOTT’S LEGACY: KITES FOR A CURE
July 20, 2014, Deal, NJ
Elliott’s Legacy: Kites for a Cure celebrated its seventh anniversary
in 2014. More than 800 people attended the fun family carnival
and kite-fly, raising nearly $500,000 for lung cancer research
and awareness. Activities included decorating kites with messages
of hope or in memory of loved ones.
The annual summer event honors Elliot Chalmé, a kite enthusiast
and avid cyclist who was taken from his family and friends at age
56 by lung cancer. Since its inception, the event has generated
more than $3.6 million for lung cancer research.
TOP LEFT The Chalmé Family enjoying the event.
TOP RIGHT Kites decorated by young attendees .
BOTTOM A view of the event, attended by over 800 people.
7
2014 ANNUAL REPORT
LCRF 2014 GRANTEES
PRINCIPAL INVESTIGATOR
RESEARCH PROJECT
INSTITUTION
Mohamed Abazeed, MD, PhD
NFE2L2 is a novel biomarker of therapeutic resistance
in non-small cell lung cancer
Cleveland Clinic
Foundation
Yanis Boumber, MD, PhD
Preclinical efficacy and mechanistic studies of STA-12-8666,
a novel HSP90-inhibitor drug conjugate to SN38 (HDC SN-38),
in lung cancer
The Research Institute
of Fox Chase
Cancer Center
John Brognard, PhD
TNIK: A novel therapeutic target for lung squamous cell cancer
University of Manchester
Ross L. Cagan, PhD
Impact of rare genetic variants on lung squamous
cell carcinoma progression
Icahn School of Medicine
at Mount Sinai
Warren Denning, PhD*
Investigation of chimeric antigen receptor T cells as a novel
immunotherapy for small cell lung cancer
University of Texas
MD Anderson Cancer Center
Christine L. Hann, MD, PhD
Developing combined Bcl-2 and mTOR inhibitor therapy
for the treatment of small cell lung cancer
Johns Hopkins
University
Faye Johnson, MD, PhD
Developing combined Bcl-2 and mTOR inhibitor therapy
for the treatment of small cell lung cancer
University of Texas
MD Anderson Cancer Center
Nikhil Joshi, PhD
Therapeutic modulation of regulatory T cell function
in a mouse model of lung adenocarcinoma
Massachusetts Institute
of Technology
Donald W. Kufe, MD
Targeting the MUC1-C oncoprotein with new agents
in drug resistant non-small cell lung cancer
Dana-Farber
Cancer Institute
Linda Malkas, PhD
Evaluation of a synthetic lethal interactor targeting
a small cell lung cancer patient subset
City of Hope
Medical Center
Linde Miles
Mechanism of Seneca Valley Virus tropism by pooled
genome-wide loss of function screening
Memorial Sloan
Kettering Cancer Center
Don Nguyen, PhD
Targeting cellular proteostasis to inhibit lung cancer metastasis
Yale University
Sharon R. Pine, PhD
Sox9 inhibition for treatment
of lung adenocarcinoma
Rutgers Cancer
Institute of New Jersey
Dan J. Raz, MD
Utilization and perceptions of lung cancer screening
among primary care physicians
City of Hope
Medical Center
Yoshiyuki Shibata, PhD
MicroDNAs as novel blood-borne biomarkers for lung cancer
University of Virginia
Tuomas Tammela, MD, PhD
Molecular mechanisms of tumor heterogeneity
in lung cancer
Massachusetts Institute
of Technology
Victoria H. Wang, MD, PhD
Drug resistance and tumor recurrence in non-small cell
lung cancer through modulation of the cytoskeleton
University of California,
San Francisco
Ralph W. Weichselbaum, MD
RLR-dependent mechanisms of interferon induction
by ionizing radiation in lung cancer cells
The University
of Chicago
Bruce Zetter, PhD
The mechanistic role of prohibitin 1 in non-small
cell lung cancer
Boston Children’s Hospital
Xiaoyang Zhang, PhD
To characterize the role of MGA loss-of-function
mutations in lung adenocarcinoma.
Dana-Farber
Cancer Institute
Grants of $50,000 over one year *Scientific Merit Award Recipient
8
BREATHING LIFE INTO RESEARCH
UALC 2014 GRANTEES
PRINCIPAL INVESTIGATOR
RESEARCH PROJECT
INSTITUTION
Arnaud Augert, PhD
Genetic models and targeted therapy for MLL2-mutant
small cell lung cancer
Fred Hutchinson
Cancer Research Center
Andrew Beardsley, MD, PhD
Targeting of cell-cell adhesion in non-small cell lung cancer
as a novel therapeutic approach
University of California,
San Francisco
Lauren Byers, MD, MS
Chk1 as a novel target in small cell lung cancer
University of Texas
MD Anderson Cancer Center
Camilla Christensen Ross, PhD
Targeting transcriptional addictions in small cell lung cancer
Dana-Farber
Cancer Institute
Eric Collison, MD
The roles of NF1 and MET mutations in lung adenocarcinoma
University of California,
San Francisco
Don Gibbons, MD, PhD
Treatment resistance to immune checkpoint inhibition
of the PD-1/PD-L1 Axis
University of Texas
MD Anderson Cancer Center
Piro Lito, MD, PhD
Direct targeting of ERK as a therapeutic modality against
non-small cell lung cancer
Memorial Sloan Kettering
Cancer Center
Edmund Moon, MD
Preventing solid tumor induced TCR engineered
T Cell hypofunction
University of
Pennsylvania
Zofia Piotrowska, MD, MHS
Allelic burden of T790M as a biomarker of response
to 3rd-generation EGFR inhibitors
Massachusetts
General Hospital
Andrea Ventura, MD, PhD
In vivo characterization of sensitivity and resistance
to Alk inhibitors using a new pre-clinical model of
Eml4-Alk-driven lung cancer
Memorial Sloan Kettering
Cancer Center
Hailun Wang, PhD
Twist1-induced NOX4-dependent oncogenic ROS as
a mechanism for erlotinib resistance in EGFR mutant
lung cancer
Johns Hopkins University
School of Medicine
Monte Winslow, PhD
Novel metastasis-specific vulnerabilities: therapeutic
targets for advanced lung adenocarcinoma
Stanford University
Grants of $100,000 over two years
9
BREATHING LIFE INTO RESEARCH
LCRF Donors 2014
$100,000–$999,999
Institutional
Good Samaritan, Inc.
$50,000–$99,999
Institutional
Bristol-Myers Squibb
Individual
Amalia Dayan Lindemann and Adam Lindemann
Kimberly Kravis and Jonathan Schulhof
Marie-Josée and Henry Kravis
Debbie and Jeffrey Resnick
Laure Sudreau-Rippe and William Rippe
Estate of Sandra K. Wilson
$25,000–$49,999
Institutional
Bloomberg Philanthropies
Cablevision Systems Corporation
Chopard
Individual
Stephanie and Chase Coleman
Pippa and Robert Gerard
Helene and Abraham Kaplan
$10,000–$24,999
Institutional
Bloomingdale’s
Dior
Elaine Terner Cooper Foundation
Goldman Sachs
Jane and Francis Stein Foundation
Kate Shea Foundation
Tania and Brian Higgins
The Ironhill Foundation
The Marc Haas Foundation
The RealReal, Inc.
Individual
Erica and Scott Belsky
Lisa and Jeff Blau
Suzanne and Stephen Farley
Laura and Peter Grauer
Amy and John Griffin
Shoshanna Gruss
Frayda B. Lindemann
David B. Murphy
Andrea Palin Fayer and Jack Fayer
Alessandra Rampogna and Alan Mnuchin
Jacqueline and Mortimer Sackler
Cynthia and Bruce Sherman
Fredericka and Howard Stevenson
Tracy and Timothy Stuart
Rose Ann and Jeffrey Weinstein
Michele and Jerry Wolkoff
Karen and Gary Yablon
11
BREATHING LIFE INTO RESEARCH
UALC DONORS 2014
CONTINUED
$10,000–$24,999
Institutional
21st Century Fox
Ariel Property Advisors
Avenue Capital Group
Bloomberg L.P.
BNY Mellon
Coach Inc.
Condé Nast
Credit Suisse
Equity Office Properties
Forest City Ratner Companies
Gateway Builders Corporation
General Restoration Contracting
Gensler
Hines Interests LP
Mack Real Estate Group
Malinsky Family Charitable Trust
Massey Knakal Realty Services
Medical Research Charities
Memorial Healthcare System
Novartis
Pfizer
Prudential Douglas Elliman
Rechler Equity Partners
RXR Realty LLC
S&C Kushner Family Foundation
Savitt Partners
Scott and Julie Latham Foundation
Signature Bank
The Edward John & Patricia Rosenwald Foundation
The Feil Family Foundation
Thornton Tomasetti
Waterman Interests, LLC
Benjamin Winter
Individual
Dan Blanco and Family
Aine Brazil and John Whelan
Rob Densen
Roxanne Donovan and Thomas Scarangello
$5,000–$9,999
Institutional
Acadia Realty Trust
Blum Family Foundation
Century 21 Associates Foundation Inc.
Esther and Joseph Shamah Foundation
First Long Island Investors, LLC
Foundation Medicine
Herrick, Feinstein LLP
I Chera & Sons Foundation, Inc.
Jack Resnick & Sons Inc.
Jones Lang LaSalle
Kohn Pedersen Fox Associates P.C.
L Brands
Maximus Foundation
Newmark Grubb Knight Frank
Park Tower Group
Roche Innovation Center New York
Rosenberg & Estis, P.C.
Soho Properties
STV Inc.
Ted Moudis Associates
The Corcoran Group
The Litwin Foundation, Inc.
The Real Estate Board of New York
The Related Companies, LLC
Washington Square Partners
WPP
Individual
Max Cohen
Christie and Anthony De Nicola
Michael Esposito
Judy and Phil Futterman
Paula and Jeffrey Gural
Icon Interiors, Inc.
Amy and Daniel Jurkowitz
Carolyn Malinsky
15
2014 ANNUAL REPORT
UALC DONORS 2014
CONTINUED
$1,000–$4,999
Individual
Edward Fallack
Moey Fallas
Jack Farrell
Irving Feldman
Zuny Fernandez
Dale Ford
Arlette and Jeffery Franco
Jack Franco
Paula Gerden and Franny McNeive
MaryAnne and James Gilmartin
S. Robert Gittlin
Lois and Bobby Glick
Susan and Andrew Goldberg
Ellen and Allen Goldman
Wendy Goldstein and Delbert McClinton
Susan and Ken Gordon
Daniel Goscicki
Eli Gottlieb
Carolyn and Gordon Grandjean
Michael Grant
Celeste Gudas
Steven Gutenplan
Millo and Sam Haddad
Jack Haddad
Charles Hadid
Priscilla and Ted Hammer
Edmond Harary
Erleen Hatfield
Susan Hausler
Grant Herlitz
Regina and Marc Hiatrides
Stephen Hill
Harriette and Paul Hirsch
Carol and Richard Hochman
Edmund D. Hollander
Richard Holowchak
Donald Huffner
Anita and Steven Iaco
Michael Ile
Scott Ingold
David Israni
Lisa Jakob
Samuel Jemal
Norman Jemal
16
Sabrina Kanner
Daniel Kaplan
Michelle and Robert Karin
Michael Kempner
Lynn and Sid King
Lynne and Caleb Koeppel
Stu Kotler
Mary Ellen and Mark Kris
Albert Laboz
David Lefkowitz
Pamela and Anthony Leichter
Margie and Steve Levy
A. Mitti Liebersohn
Matt Lytell
Joyce and Stanley Magid
Michelle and Jack Maleh
Jack Mann
Lori Marks-Esterman
Mark and Isaac Massry
Joan Meixner
Jodi and Kenneth Meyerson
Morris Missry
Jean and Marshall Mizrahi
Oliver Moses
Donna and Patrick Murphy
Mary H. Naegeli
Steven Nakash
Cherrie Nanninga
Lan Nguyen
Martin Nussbaum
Kevin O’Brien
Liz and Augustus Oliver
Jean Osberg
Albert Pardo
Caroline and David Perez
Anna Plaza
Stephen Polivy
Ginny and Richard Poveromo
Ray Quartararo
Peter Rip
Peter Ripka
Jennifer Rivera
Lori and Rene Rofe
BREATHING LIFE INTO RESEARCH
UALC DONORS 2014
CONTINUED
$1,000–$4,999
Individual
Elizabeth Rote
Stanley Rothstein
Heidi and Steve Russo
Amy and Steven Sasson
Steven Sasson
Catherine and Andrew Scandalios
Harvey Schonbrun
Lori and Owen Schwartz
Frank J. Sciame
Terry Seay
Donna and Stewart Senter
Elliot Shalom
Jack Shamosh
Dianna and David Shipley
Leon Shpunt
Ken Shuckman
Gregory Shunick
Jacqueline Albert Simon
Terri and Morris Sitt
Joseph Sitt
Paul Skelton
Joe Skrzypczak
Audrey and Marc Solomon
Darcy Stacom
Ruth Steinberg
Robin and David Stonehill
Tami Stubblefield
Moshe Sukenik
Saif Sumaida
Jeff Sutton
Nicole Swartzentruber
Alexander Sweetwood
Saul Tawil
Elliot Tawil
Laura and Joseph Tawil
Kerry and Michael Tepedino
Virginia and Frank Terrazzano
Jack Terzi
Kimberly and Brown Thornton
Kimberly and Aaron Tighe
Andrea and Richard Tomasetti
Nadine and Arthur Waldbaum
Nancy Waldbaum
Mary Weinberg
Stephan Weiss
Lorrie and Edwin Wiley
Robyn Wilson
Eli Yedid
Simon Ziff
Martin Zubatkin
Penny Zuckerwise
17
2014 ANNUAL REPORT
Financial Overview
LCRF 2014 FINANCIAL OVERVIEW
LUNG CANCER RESEARCH FOUNDATION
STATEMENTS OF FINANCIAL POSITION
Assets
Cash and cash equivalents
$1,151,991
Pledges and contributions receivable
$49,545
Other assets
$31,086
Total assets
$1,232,622
Liabilities and Net Assets
Liabilities
Accounts payable and accrued expenses
$36,983
Net assets
Unrestricted
Total liabilities and net assets
$1,195,639
$1,232,622
STATEMENT OF ACTIVITIES
Public support and revenue
Contributions
$610,454
Revenue from special events
Gross receipts
$1,225,960
Less: direct costs
($177,553)
Net revenue from special events
Investment income
Total public support and revenue
$1,048,407
$1,792
$1,660,653
Expenses
Program services
Management and general
Fundraising
Total expenses
Decrease in net assets
$1,188,406
$270,539
$295,842
$1,754,787
($94,134)
NET ASSETS – BEGINNING OF YEAR
$1,289,773
NET ASSETS – END OF YEAR
$1,195,639
18
BREATHING LIFE INTO RESEARCH
UALC 2014 FINANCIAL OVERVIEW
UNITING AGAINST LUNG CANCER
STATEMENTS OF FINANCIAL POSITION
Assets
Cash and cash equivalents
Contributions receivable
Prepaid expenses
Property and equipment, net
$1,939,444
$285,384
$22,087
$9,542
Other assets
$11,040
Total assets
$2,267,497
Liabilities and Net Assets
Liabilities
Accrued expenses and other payables
$63,667
Grants payable
$842,370
Total liabilities
$906,037
Net assets
Unrestricted
$1,261,460
Temporarily restricted
$100,000
Total net assets
Total liabilities and net assets
$1,361,460
$2,267,497
STATEMENT OF ACTIVITIES
Support and revenue
Revenue from special events
Gross receipts
$2,468,989
Less: cost of direct benefits to donors
($267,038)
Net revenue from special events
Total Contributions
Unrestricted
Temporarily restricted
In kind donations
Interest and dividends
Other income
Total support and revenue
$2,201,951
$732,181
$632,181
$100,000
$201,268
$12,807
$908
$3,149,115
Expenses
Program services
Management and general
Fundraising and development
Total expenses
Change in net assets
$2,319,007
$126,783
$392,401
$2,838,191
$310,924
NET ASSETS – BEGINNING OF YEAR
$1,050,536
NET ASSETS – END OF YEAR
$1,361,460
19
2014 ANNUAL REPORT
2014 Board of Directors
LCRF BOARD OF DIRECTORS
UALC BOARD OF DIRECTORS
Pippa G. Gerard
Chairman of the Board
Mary Ann Tighe
President
Kimberly Kravis
Vice Chairman
Meryl L. Bralower
James B. Dougherty, MD
Chair, Scientific Advisory Board
William C. Rippe
Co-Treasurer
Laure Sudreau-Rippe
Co-Treasurer
David Monk
Secretary
Shabnam Kazmi
Amalia Dayan Lindemann
Alan Mnuchin
Lara Stein
Rose Ann Weinstein
20
Raymond Chalmé
Roxanne Donovan
Wendy Goldstein
David Hidalgo
Pavi Micheli Lawson
Thomas Scarangello
Ronald D. Sernau
Aaron M. Tighe
Patrick T. McNeive
President Emeritus
BREATHING LIFE INTO RESEARCH
2015 Board of Directors & Executive Team
LCRF BOARD OF DIRECTORS
LCRF EXECUTIVE TEAM
Pippa G. Gerard
Chairman
Kimberly Kravis
Vice Chairman
Mary Ann Tighe
Vice Chairman
James B. Dougherty, MD
Chair, Scientific Advisory Board
Nancy M. Sanford
Executive Director
Brendon M. Stiles, MD
Vice Chair, Scientific Advisory Board
Aaron M. Tighe
Treasurer
Laure Sudreau-Rippe
Secretary
Delia Naughton, LMSW
Vice President of Business Development
Meryl L. Bralower
Raymond E. Chalmé
David A. Hidalgo, MD
Amalia Dayan Lindemann
Alan G. Mnuchin
Jan Baranski, PhD
Director of Scientific Programs
David Monk
Ronald D. Sernau
Lara Stein
Rose Ann Weinstein
21
BREATHING LIFE INTO RESEARCH
23
BREATHING LIFE INTO RESEARCH
B R E AT H I N G L I F E I N T O R E S E A R C H
155 East 55th Street, Suite 6H, New York, NY 10022
Tel: 212.588.1580 | Fax: 212.308.0972 | info@lungfund.org
www.lungfund.org
LCRF is a 501(c)(3) public charity. Federal Tax ID #14-1935776 Privacy Policy © Copyright 2015 LCRF
24